Cargando…

Moving beyond PARP Inhibition: Current State and Future Perspectives in Breast Cancer

Breast cancer is the most frequent and lethal tumor in women and finding the best therapeutic strategy for each patient is an important challenge. PARP inhibitors (PARPis) are the first, clinically approved drugs designed to exploit synthetic lethality in tumors harboring BRCA1/2 mutations. Recent e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Palleschi, Michela, Tedaldi, Gianluca, Sirico, Marianna, Virga, Alessandra, Ulivi, Paola, De Giorgi, Ugo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8346118/ https://www.ncbi.nlm.nih.gov/pubmed/34360649 http://dx.doi.org/10.3390/ijms22157884

Ejemplares similares

Cell-Free DNA Fragmentomics: A Promising Biomarker for Diagnosis, Prognosis and Prediction of Response in Breast Cancer
por: Gianni, Caterina, et al.
Publicado: (2022)

Current State and Future Challenges for PI3K Inhibitors in Cancer Therapy
por: Sirico, Marianna, et al.
Publicado: (2023)

Treatment of Ovarian Cancer Beyond PARP Inhibition: Current and Future Options
por: Garg, Vikas, et al.
Publicado: (2023)

Primary Mediastinal and Testicular Germ Cell Tumors in Adolescents and Adults: A Comparison of Genomic Alterations and Clinical Implications
por: Urbini, Milena, et al.
Publicado: (2021)

Emerging Role of PARP Inhibitors in Metastatic Triple Negative Breast Cancer. Current Scenario and Future Perspectives
por: Barchiesi, Giacomo, et al.
Publicado: (2021)

Potential Impact of Preoperative Circulating Biomarkers on Individual Escalating/de-Escalating Strategies in Early Breast Cancer
por: Gianni, Caterina, et al.
Publicado: (2022)

Current and Future Directions for PARP Inhibition
por: Grudem, Megan, et al.
Publicado: (2020)

Beyond N staging in colorectal cancer: Current approaches and future perspectives
por: Arrichiello, Gianluca, et al.
Publicado: (2022)

Circulating inflammatory cells in patients with metastatic breast cancer: Implications for treatment
por: Gianni, Caterina, et al.
Publicado: (2022)

Current Evidence and Future Perspectives about the Role of PARP Inhibitors in the Treatment of Thoracic Cancers
por: Parisi, Alessandro, et al.
Publicado: (2023)

Clinical Impact of Next-Generation Sequencing Multi-Gene Panel Highlighting the Landscape of Germline Alterations in Ovarian Cancer Patients
por: Gurioli, Giorgia, et al.
Publicado: (2022)

Back to the Future: Moving Beyond “Mesenchymal Stem Cells”
por: Bianco, Paolo
Publicado: (2011)

Genetic Predisposition to Colorectal Cancer: How Many and Which Genes to Test?
por: Rebuzzi, Francesca, et al.
Publicado: (2023)

Locoregional treatment of de novo stage IV breast cancer in the era of modern oncology
por: Merloni, Filippo, et al.
Publicado: (2023)

PARP Inhibitors in Endometrial Cancer: Current Status and Perspectives
por: Musacchio, Lucia, et al.
Publicado: (2020)

Moving beyond the Slit-Lamp Gonioscopy: Challenges and Future Opportunities
por: Cutolo, Carlo Alberto, et al.
Publicado: (2021)

Oligometastatic breast cancer and metastasis-directed treatment: an aggressive multimodal approach to reach the cure
por: Merloni, Filippo, et al.
Publicado: (2023)

Impact of Somatic DNA Repair Mutations on the Clinical Outcomes of Bone Metastases from Castration-Resistant Prostate Cancer
por: Cursano, Maria Concetta, et al.
Publicado: (2023)

Stat1 confers sensitivity to radiation in cervical cancer cells by controlling Parp1 levels: a new perspective for Parp1 inhibition
por: Raspaglio, Giuseppina, et al.
Publicado: (2021)

Moving Beyond the Brain: Transcutaneous Spinal Direct Current Stimulation in Post-Stroke Aphasia
por: Marangolo, Paola, et al.
Publicado: (2017)

PARP inhibitors in the management of breast cancer: current data and future prospects
por: Livraghi, Luca, et al.
Publicado: (2015)

Moving Beyond the Pillars of Cancer Treatment: Perspectives From Nanotechnology
por: Siamof, Cerise M., et al.
Publicado: (2020)

PARP Inhibitors in Cancer Therapy: Magic Bullets but Moving Targets
por: Shah, Girish M., et al.
Publicado: (2013)

Lupus Nephritis: Current Perspectives and Moving Forward
por: Lichtnekert, Julia, et al.
Publicado: (2022)

Moving beyond MTBE.
por: Tenenbaum, D J
Publicado: (2000)

Moving beyond COVID
por: Tandon, Rajiv
Publicado: (2022)

Moving beyond Titers
por: Brooks, Benjamin D., et al.
Publicado: (2022)

Moving beyond MARCO
por: Rosa, Nicholas, et al.
Publicado: (2023)

PARP Inhibitors as Therapeutics: Beyond Modulation of PARylation
por: Min, Ahrum, et al.
Publicado: (2020)

Peritoneal Dialysis—Moving from Current Status to the Future
por: Oh, Kook-Hwan, et al.
Publicado: (2013)

Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer
por: Jiang, Xuan, et al.
Publicado: (2019)

Immunosenescence in Testicular Cancer Survivors: Potential Implications of Cancer Therapies and Psychological Distress
por: De Padova, Silvia, et al.
Publicado: (2021)

Cell-free DNA as a diagnostic marker for cancer: current insights
por: Salvi, Samanta, et al.
Publicado: (2016)

Telemedicine, the current COVID-19 pandemic and the future: a narrative review and perspectives moving forward in the USA
por: Kichloo, Asim, et al.
Publicado: (2020)

PARP Power: A Structural Perspective on PARP1, PARP2, and PARP3 in DNA Damage Repair and Nucleosome Remodelling
por: van Beek, Lotte, et al.
Publicado: (2021)

The Role of PARP1 in Monocyte and Macrophage Commitment and Specification: Future Perspectives and Limitations for the Treatment of Monocyte and Macrophage Relevant Diseases with PARP Inhibitors
por: Sobczak, Maciej, et al.
Publicado: (2020)

Advances and perspectives of PARP inhibitors
por: Yi, Ming, et al.
Publicado: (2019)

Two-dimensional nanomaterials beyond graphene for antibacterial applications: current progress and future perspectives
por: Mei, Linqiang, et al.
Publicado: (2020)

Editorial: The Future of Work in Non-profit and Religious Organizations: Current and Future Perspectives and Concerns
por: Ariza-Montes, Antonio, et al.
Publicado: (2020)

Moving beyond GK–12
por: Ufnar, J. A., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_d7opuver8ls8hp3e75ks7opndu